FDA under renewed fire over dubious approval of Alzheimer’s drug
By EsqSocial Corporation 06/12/21
Taxpayers and patients are suffering the rising negative consequences of the federal Food and Drug Administration’s dubious decision to overrule its own independent expert advisors and to approve on scant evidence Aduhelm. It is a prescription drug targeting Alzheimer’s disease, and concerns are rising about the medication’s safety and costs, not to mention whether it really works....
By: Patrick Malone & Associates P.C. | DC Injury